Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus (Q38085691)

28 August 2017

title

Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus (English)

1 reference

28 August 2017

0 references

William N Washburn

1

1 reference

28 August 2017

Simon M Poucher

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 March 2013

1 reference

Expert Opinion on Investigational Drugs

28 August 2017

published in

1 reference

28 August 2017

volume

22

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

463-486

1 reference

Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Glucose control by the kidney: an emerging target in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Sugar uptake into brush border vesicles from normal human kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Rat renal glucose transporter SGLT1 exhibits zonal distribution and androgen-dependent gender differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Active sugar transport in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Regulation of the human Na+-dependent glucose cotransporter hSGLT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

The Sweet Pee model for Sglt2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

SGLT2 mediates glucose reabsorption in the early proximal tubule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Relative expression of a dominant mutated ABCC8 allele determines the clinical manifestation of congenital hyperinsulinism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Damaging loss of self-control by stressed β-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.774372

10.1517/13543784.2013.774372

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference